Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer

2026-03-07 17:12:51

Zevra Therapeutics, a commercial-stage company focused on rare disease therapies, announced the appointment of Justin Renz as its new Chief Financial Officer, effective March 9, 2026. Renz brings over 25 years of financial leadership experience in the biopharmaceutical industry, with a strong background in capital markets, strategic transactions, and commercial operations. His appointment is expected to strengthen the company’s financial foundation and support its growth strategy in the rare disease sector.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.